ACR Convergence 2022

November 10-14, 2022. Philadelphia, PA.

View by Number View by Title View Sessions

View by Date

Sunday, November 13, 2022

9:00AM-10:30AM: Abstract Number: 0611

Proteomics Reveals Dysregulated Molecular Mechanisms of Cell Death in Neutrophils in Rheumatoid Arthritis

RA – Etiology and Pathogenesis Poster

9:00AM-10:30AM: Abstract Number: 0837

Providers’ Adoption of 2017 Guidelines on DMARD Use Perioperatively for Elective Total Hip and Knee Arthroplasty at a Single Academic Center

Orthopedics, Low Back Pain, and Rehabilitation Poster

9:00AM-10:30AM: Abstract Number: 1090

Pulmonary Function Testing (PFT) in Patients with Antineutrophil Cytoplasmic Antibodies (ANCA)-associated Vasculitis (AAV): Correlation with Radiologic Imaging

Vasculitis – ANCA-Associated Poster II: Treatment Efficacy, Clinical Outcomes, Biomarkers

9:00AM-10:30AM: Abstract Number: 0823

Pulmonary Manifestations in VEXAS (Vacuoles, E1 Enzyme, X-linked, Autoinflammatory, Somatic) Syndrome: A Systematic Literature Review

Miscellaneous Rheumatic and Inflammatory Diseases Poster II

9:00AM-10:30AM: Abstract Number: 0981

QTc Prolongation in Rheumatoid Arthritis and Systemic Lupus Erythematosus Patients Treated with Hydroxychloroquine – Preliminary Results from a Single Center Study

SLE – Treatment Poster II

9:00AM-10:30AM: Abstract Number: 0750

Quality Improvement Project to Increase the Rate of Vaccination with Pneumococcal Vaccines (PCV13 prime-PPSV23 Boost Strategy) Among Adult Patients with Autoimmune Inflammatory Rheumatic Diseases (AIIRD) Within Nationwide Health Organization

Health Services Research Poster II

9:00AM-10:30AM: Abstract Number: 1045

Quantification of the Enthesic Response to Biological Therapies in Patients with Spondyloarthritis by Computer Analysis of Ultrasound Images

Spondyloarthritis Including PsA – Treatment Poster II: Mixed

9:00AM-10:30AM: Abstract Number: 0728

Racial Disparities in Pain: Severity, Interference with Function, and Response to Guided Imagery

Health Services Research Poster II

9:00AM-10:30AM: Abstract Number: 0843

Racial Disparities in Patient Satisfaction Following Total Joint Arthroplasty: A Contemporary Trends Analysis from 2013-2021

Orthopedics, Low Back Pain, and Rehabilitation Poster

9:00AM-10:30AM: Abstract Number: 0974

Rapid Efficacy of Anifrolumab Across Multiple Subtypes of Recalcitrant Cutaneous Lupus Erythematosus Parallels Discrete Changes in Transcriptomic and Cellular Biomarkers

SLE – Treatment Poster II

9:00AM-10:30AM: Abstract Number: 0740

Real-World Demographics, Clinical Characteristics, and Treatment Patterns of Patients Treated with Emapalumab for Secondary Hemophagocytic Lymphohistiocytosis in the United States: The REAL-HLH Study

Health Services Research Poster II

9:00AM-10:30AM: Abstract Number: 0714

Real-World Treatment Effectiveness of Disease-Modifying Anti-Rheumatic Drugs by Serostatus Among Patients with Rheumatoid Arthritis

Epidemiology and Public Health Poster I

9:00AM-10:30AM: Abstract Number: 0897

Reasons for Multiple Biologic DMARD Switching and Characteristics of “Extreme Treatment Nonresponders” in Rheumatoid Arthritis

RA – Diagnosis, Manifestations, and Outcomes Poster II

9:00AM-10:30AM: Abstract Number: 0701

Reduced Humoral but Maintained Cellular Immune Response to a 3rd COVID-19 Vaccination in Patients with Immune-Mediated Inflammatory Diseases as Compared to Healthy Controls over a 3-months Observational Period

Epidemiology and Public Health Poster I

9:00AM-10:30AM: Abstract Number: 0637

Reduced IgG Sialic Acid Content: A Distinctive Characteristic of Symptomatic Anti-Nuclear Antibodies Positive Individuals

SLE – Etiology and Pathogenesis Poster

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].